Baker Lh

410 citations
31 papers · 300 indexed · h-index 12

Baker Lh

30 papers receiving 267 citations

Peers

Baker Lh
Comparison fields: 5 of 64
  • Oncology 169
  • Toxicology 11
  • Hepatology 18
  • Pulmonary and Respiratory Medicine 71
  • Pathology and Forensic Medicine 35
Replace Masaji Yamauchi with:
Masaji Yamauchi Japan
J H Scarffe United Kingdom
G. Stathopoulos Greece
W. ten Bokkel Huinink Netherlands
V. Barbounis Greece
M Steger United States
Jennifer Marks Canada
A. Antón Torres Spain
Suebpong Tanasanvimon Thailand
Vladimir Kovčin Serbia
Baker Lh relative to Masaji Yamauchi Japan Masaji Yamauchi's profile →
Citations per field
00.5×4.5×
Masaji Yamauchi · 1×
Citations per year

Countries citing papers authored by Baker Lh

Since Specialization
Citations

This map shows the geographic impact of Baker Lh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Baker Lh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Baker Lh more than expected).

Fields of papers citing papers by Baker Lh

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Baker Lh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Baker Lh. The network helps show where Baker Lh may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Baker Lh, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Baker Lh Line = papers co-authored together Baker Lh links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1
Phase II trial of diaziquone in patients with refractory and relapsing multiple myeloma: a Southwest Oncology Group Study.
19873
2
Phase I study of echinomycin.
198710
3
Phase II trial of diaziquone in advanced large bowel carcinoma in previously treated and untreated patients: a Southwest Oncology Group Study.
19852
4
PCNU in advanced adenocarcinoma of the ovary: a phase II study.
19833
5
Gallium nitrate in malignant lymphoma: a Southwest Oncology Group study.
198324
6
Phase II evaluation of gallium nitrate in breast cancer: a Southwest Oncology Group Study.
19827
7
Clinical trial of chlorozotocin, DTIC, and dactinomycin in metastatic malignant melanoma.
19823
8
Phase II study of high-dose intermittent cycloleucine in colorectal malignancies.
19822
9
Mitomycin C and bleomycin in the treatment of far-advanced cervical cancer: a Southwest Oncology Group pilot study.
198113
10
Phase I-II clinical trial of gallium nitrate (NSC-15200).
198012
11
American experience with carminomycin.
197910
12
Use of VM-26 as a single agent in the treatment of renal carcinoma.
19799
13
Clinical trial of rubidazone in advanced squamous cell carcinoma of the lung and adenocarcinoma of the large intestine.
19782
14
Combination chemotherapy with cyclophosphamide, vincristine, methyl-CCNU, and bleomycin in advanced bronchogenic carcinoma: experience with 106 patients.
19773
15
5-FU infusion and cyclophosphamide in the treatment of advanced ovarian cancer.
19774
16
Adriamycin and 5-fluorouracil in the treatment of advanced hepatoma: a Southwest Oncology Group study.
197718
17
Phase I and II evaluation of cytembena in disseminated epithelial ovarian cancers and sarcomas.
19763
18
Phase I clinical trial of combined therapy with vinblastine (NSC-49842), bleomycin (NSC-125066), and cisdichlorodiammineplatinum(II)( NSC-119875).
197617
19
Phase I study of oral mitomycin C.
197615
20
Bony metastasis from adenocarcinoma of the colon.
19748

About Baker Lh

Baker Lh is a scholar working on Reproductive Medicine, Small Animals, Oncology, Pulmonary and Respiratory Medicine and Toxicology, having authored 31 papers that have together received 300 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (7 papers), Cancer therapeutics and mechanisms (6 papers), Radiopharmaceutical Chemistry and Applications (4 papers), Ovarian cancer diagnosis and treatment (4 papers), Cancer Treatment and Pharmacology (4 papers), Antifungal resistance and susceptibility (3 papers), Lung Cancer Research Studies (3 papers) and Infectious Diseases and Mycology (3 papers). The work is most often cited by research in Oncology (169 citations), Toxicology (11 citations), Hepatology (18 citations), Pulmonary and Respiratory Medicine (71 citations) and Pathology and Forensic Medicine (35 citations). Baker Lh has collaborated with scholars based in United States. Frequent co-authors include Richard Stephens, J J Costanzi, Jones Se, Joseph M. Quagliana, E. Gehan, Talley Rw, Weick Jk, Michael Henderson, Priyanka A. Shah and Michael K. Samson. Their work appears in journals such as Journal of Clinical Oncology, Lung Cancer, European Journal of Cancer and PubMed.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026